Bio-Modeling Systems: The Mechanisms-Based Mecidicine Company
  • 2019: ANNOUNCEMENT: Lyon October 17-18, 2019: Bio-Modeling Systems invited at the India-France Knowledge Summit 2 to contribute with its CADI Discovery Platform, the other AI, successfully applied to its Indo-French  metabolic disorders therapeutic program UMANG (now Arbuza Regenerate company) addressing  a public health issue concerning 50-100 millions children.
  • 2019: PRESS RELEASE: Paris October 1, 2019: Bio-Modeling Systems, the Mechanisms-Based Cosmetics company, is invited to present its CADI™ Discovery platform and 7 outputs at the open Innovation sessions of Cosmetic-360

  • 2019: ANNOUNCEMENT: Lille Juily 2-4, 2019: BMSystems invited as speaker at ANTIMIC 2019: Bacteriophages, Genius and success of precision medicine in infections (ATC HCl) and new tracks for microbiote “surgery” controt with GEMMA microbiota &Autism H2O2O program
  • 2019: PRESS-RELEASE: Paris May 30, 2019 : Manuel GEA, CEO BMSystems, rejoint l’Advisory Board Pharma/Santé de Bolero pour renforcer leurs offres et accélérer la convergence recherche clinique et données de vraie vie

  • 2019: ANNOUNCEMENT: Paris May 5, 2019: Bio-Modeling Systems is participating to Neurodegenerative Drug Development Europe Conference in Paris (May 22-23, 2019). Meet us to discover our Alzheimer's and Parkinson’s diseases solutions.
  • 2019: ANNOUNCEMENT: BMSystems will be participating to  Polepharma microbiota conference (the N°1 pharmaceutical cluster in Europe) event to present its GEMMA microbiota &Autism H2O2O program !
  • 2019: PRESS-RELEASE: Paris April  2, 2019: Bio-Modeling Systems, the 14 M€ H2020 GEMMA (Autism and Microbiota) integrative biology partner, announces the release of the public program web site: for the World Autism Awareness Day.
  • 2019-NEW-YEAR PROGRAM: Paris January 24, 2019: In 2019, our founding motto: “Understand disease mechanisms first. Adapted treatments will follow.” is still highly relevant. FRENCH

  • 2018: POSITION PAPER : Paris December 2, 2018: SMART STRATEGY vs. BIG STRATEGY: How Augmented Intelligence, the other AI, addresses the digital “garbage in garbage out” reality and the life complexity

  • 2018: ANNOUNCEMENT: BMSystems invited to present its CADI Discovery platform and achievements at 4 events in Europe,BioFit,-BioWin-Day,COST EC cluster conference, DGA BtoB  

Bio-Modeling Systems: The Mechanisms-Based Mecidicine Companys

CADI™ Discovery - Research Production

CADI™ Discovery programs to date: 3 Business Units in 8 domains and 6 CADI™ Therapies:

3 Business Units

  1. Mechanisms-Based Medicine
  2. Mechanisms-Based Cosmetic
  3. Mechanisms-Based Nutrition

8 domains

  1. Infection-Immunology domain: Chronic Fatigue Syndrome / Gulf war Syndrome; Ebola virus ecology; Hepatitis C; Auto-immune global concept
  2. Micorbiotas /Microbiomes: Skin, lung, gut, etc, ecology, physiology & metabolic mechanisms. GEMMA, Microbiota & Autism H2020 program, selected for 14 M€ funding!
  3. CNS / PNS Inflammation domain: Psychiatric & neurologic treatment; Creutzfeldt-Jakob disease mechanisms; Alzheimer's Disease Mechanisms; Parkinson's Disease Treatment; Psychiatric inflammatory mechanisms; Fibromyalgia, facial pain; Pain (Central/Peripheral); Migraine Mechanisms; Multiple Sclerosis Mechanisms; Psychiatric disorders biomarkers
  4. Metabolism / Inflammation domain: Hypercholestemia Mechanisms; diabetes type 2; New global concept for Diabetes type 1; Metabolic Syndrome.
  5. Cancer / Inflammation domain: Breast cancer-Hras; Tamoxifen resistance; Specific Metastasis control; Global Metastasis control
  6. Tissue Differentiation domain: Müllerian regression Mechanisms; Adipocytes growth control
  7. Dermatology / Csosmetics / Inflammation domain: Skin Contact Allergy Mechanisms; Skin pigmentation Mechanisms; Skin pigmentation Modulation; Skin aging Mechanisms; Modulation of skin hydration; Modulation of the lipid constituents of the skin barrier; Novel Hair Loss Mechanisms
  8. Industrial Biotech domain: Program Synthons; industrial biotech; Human Glycosylation with Yeast
  • Rare diseases/ Orphan diseases/ Orphan drugs based on CADI™ Discovery repositioning

7 CADI™ Combo-Therapies and 1 CADI™ Combo-Diagnostic (new internal classification)


  1. CADI-T1011 Multi-Resistance Infectious Diseases
  2. CADI-T1031 CFS Low-Grade Chronic Inflammation
  3. CADI-T1032 Gulf War Syndrome
  4. CADI-T2011 Attenuation of the Core Symptoms of Autism
  5. CADI-T3021 Parkinson's Disease
  6. CADI-T4021 Metabolic Syndrome
  7. CADI-T4031 Diseases Attenuation of Developmental Consequences of Children Malnutrition


  1. CADI-D3041 Alzheimer's Disease Early Diagnostics


14 CADI™ successes programs (partners/clients questions) to date:

For all details download our short Presentation

  1. Mechanisms of pathogenesis & clinical progression of Creutzfeldt-Jakob Disease;
  2. Mechanisms of anti-connexin agents for modulating the therapeutic effect of psychotropic and neurodegenerative drugs;
  3. Cellular & metabolic mechanisms associated with chronic anxiety;
  4. Novel antiglycemic mechanism;
  5. Anti-metastatic mechanisms of the RGD15 peptide;
  6. Mechanisms of Ras-mediated breast cancer oncogenesis;
  7. Mechanisms of breast cancer resistance to tamoxifen;
  8. Regression mechanisms of the Müllerian duct;
  9. Mechanisms of differential melanosome degradation;
  10. Context-dependent functions of OA1 protein;
  11. Context-dependent functions of OCA2 protein;
  12. Context-dependent functions of SLC45A2 (MATP) protein;
  13. Engineered bacteriophage banks and the control of multi-resistant pathogens;
  14. Bioproduction and hemisynthesis of 18-methyl eicosanoic acid;

IMPORTANT: We are not domain dependent, but smart data access dependant

Bio-Modeling Systems: a leading Integrative Heuristic Systems Biology / Predictive Integrative Biology Mechanisms-Based Medicine company that delivers